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herapeutic advances over the last 3 decades have made a
ramatic impact on mortality from atherosclerotic cardio-
ascular disease. As a result, intensive modification of
stablished risk factors has become increasingly integrated
nto guidelines designed to reduce cardiovascular risk. How-
ver, using existing therapies, event rates are reduced by no
ore than 40% in large randomized clinical trials. This
bservation suggests that residual risk will remain elevated
espite an optimal use of currently available interventions.
he expanding global burden of cardiovascular disease in
ssociation with obesity and associated metabolic risk fac-
ors is likely to further emphasize the need to develop new
trategies to complement existing therapies.
See page 1370
Increasing evidence has focused on the role of inflamma-
ion and oxidation in the initiation and progression of
therosclerosis. The early stage of plaque development
ithin the artery wall involves transudation and oxidation of
ow-density lipoprotein, with the accumulation of inflam-
atory cells and formation of foam cells. Elaboration of
roinflammatory cytokines by foam cells promotes ongoing
ccumulation of cellular and necrotic material, features that
re critical for progression and subsequent rupture of ath-
rosclerotic plaque. As a result, there is considerable interest
n these pathological cascades as targets for the development
f new biomarkers for risk prediction and novel atheropro-
ective therapies. Given the prominent roles of both inflam-
ation and oxidative stress in the setting of acute ischemic
yndromes, it is has been proposed that such novel thera-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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Despite increasing awareness of the role of these events in
therosclerosis, no new therapy specifically targeted at
educing either inflammation or oxidative stress in the artery
all has demonstrated clinical effectiveness in humans. In
articular, the consistent failure of multivitamins to prevent
ardiovascular events in large, randomized clinical trials has
rought into question the concept that oxidation plays a
ajor role in atherosclerosis (1). However, because no index
f oxidative stress was quantified in these trials, it remains
nknown whether these interventions had any impact on
xidation within the vessel wall. In addition, although it has
een proposed that anti-inflammatory properties contribute
o the clinical benefit of a range of established therapies, no
gent that specifically targets vascular inflammation has
hown a beneficial impact on cardiovascular risk in prospec-
ive clinical trials. As a result, it remains uncertain whether
ew agents, acting predominantly as antioxidant or anti-
nflammatory agents, will have an impact on the residual
isk of patients receiving established preventive therapies.
It seems likely that the most effective strategies will be
hose that directly modify established targets that can be
asily quantified. Oxidized forms of low-density lipoprotein
OxLDL) have received considerable interest in the devel-
pment of new biomarkers and therapies. OxLDL plays a
ivotal role in foam cell formation and propagation of
therosclerosis. Circulating levels of antibodies against
xLDL are associated with reduced levels of surrogate
arkers of atherosclerosis (2). Immunization of oxidation
pitopes evokes an antibody response and has been demon-
trated to prevent lesion formation in animal models of
therosclerosis (3). Therefore, endogenous factors that pro-
ote induction of antibodies directed against OxLDL have
he potential to prevent cardiovascular disease.
In this issue of the Journal, Sämpi et al. (4) report the
elationship between systemic levels of interleukin (IL)-5
nd antibodies to OxLDL in patients with subclinical
therosclerosis, as measured by carotid intimal-medial
hickness. Investigation of 1,011 Finnish middle-aged sub-
ects who participated in the OPERA (Oulu Project Elu-
idating Risk of Atherosclerosis) study revealed that in-
reasing plasma levels of the cytokine IL-5 was associated
ith greater levels of antibodies binding to OxLDL and less
ubclinical atherosclerosis. This extends previous findings
rom murine models (5,6) and although these data do not
stablish a causal mechanistic link, they do suggest a
otentially atheroprotective role for IL-5 via induction of
ntibodies against oxidized forms of low-density lipoprotein
LDL).
These observations further highlight the challenge of
eveloping an effective approach to prevention of cardiovas-
ular disease via protection of the vessel wall from the
onsequences of oxidative stress. Although many markers of
xidative stress have been reported in association with
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Inflammation, Oxidation, and Atherosclerosis October 21, 2008:1379–80ardiovascular disease, it is likely that interventions that
arget those oxidative mediators that directly participate in
isease propagation are more likely to be beneficial. The
ivotal role played by OxLDL throughout the entire spec-
rum of stages of atherosclerosis therefore highlights its
andidature as a factor of major interest. In a similar fashion,
t is not surprising that given that myeloperoxidase (MPO) and
ts oxidant products promote atheroma formation and rupture,
hat systemic MPO levels independently predict clinical risk
nd that MPO inhibitors have received considerable interest as
ardiovascular therapeutic agents (7).
The potential interaction between IL-5 and generation of
ntibodies directed against OxLDL also highlight the
ossibility that stimulation of endogenous antioxidant path-
ays may be beneficial. Even though many factors appear to
ossess antioxidant activities in vitro, this benefit is not
lways observed in the in vivo setting. It is likely that
dditional endogenous factors that specifically target oxida-
ion of LDL may also protect the artery wall. Increasing
vidence, for example, has highlighted the role of high-
ensity lipoproteins in the prevention of LDL oxidation and
nhibition of a number of pathways involved in generation
f oxidative stress within the artery wall (8). Therefore, it is
ossible that a potential benefit of therapies that target
igh-density lipoproteins may be derived via stimulation of
hese endogenous antioxidant activities.
The findings by Sämpi et al. (4) have important impli-
ations for the development of strategies that target inflam-
atory and oxidative cascades. The observation that a
otentially protective role of an inflammatory cytokine
nvolves the reduction of 1 of the major oxidative mediators
n the artery wall suggests that strategies that promote the
ctivity of some inflammatory cytokines may, in fact, be
rotective. Furthermore, inhibition of these pathways in the
ourse of treatment of inflammatory disease processes in-
olving other organs may result in an unwanted detrimental
K
ompact on cardiovascular disease. As the potential impact of
he crosstalk between inflammatory and oxidative pathways
n atherosclerosis becomes further elucidated, the search to
evelop new therapies to reduce cardiovascular risk just got
little more complicated.
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